Europe's Med Tech Advantage Is Real, But Only If You Build It Right with Tatiana Lobanov-Rostovsky

In this episode of the Crux of MedTech, Henry Norton is joined by Tatiana Lobanov-Rostovsky, Investor at Oxford Science Enterprises, the independent, billion-pound investment company built in partnership with the University of Oxford. With a background in neuroscience, Healthcare M&A at Rothschild & Co, and hands-on experience inside a biotech startup, Tatiana brings a rare view across the full lifecycle of medtech company building.From the Europe vs US debate to why most companies fail not in R&D but in commercial and what the best founders do differently from day one, this is a candid conversation about what it actually takes to build something the strategics will want.Key TopicsEurope vs US: where medtech startups should build, raise, and scaleThe Oxford Science Enterprises model, patient capital, EIR programmes, and venture building from university spinoutsHow to spot the difference between a technology looking for a problem and a genuine clinical pullBuilding for a strategic acquisition from day one, what the buyers actually want to seeWhy commercial talent matters more than technical talent at the early stageThe EU/UK infrastructure gaps holding back medtech foundersRelated InsightsWhy hardware companies will outlast SaaS in a world of AI disruption and what that means for medtech investorsThe NHS as a data advantage: how UK founders can use patient data to build globally competitive productsStructural heart and neurovascular as active investment themes and what's driving OSE's thesis buildingCaristo Diagnostics and Ultromics as case studies in AI-powered cardiac diagnostics scaling for the US marketCore ChallengesThe majority of medtech companies that reach FDA approval still fail in commercial, making go-to-market strategy as important as clinical validation.European founders face a structural disadvantage in accessing the right commercial talent early enough, with risk aversion and brain drain compounding the problem.Investors are paralysed by AI disruption uncertainty, but hardware-first, highly regulated sectors like medtech remain defensible, if founders and investors are willing to think long-term.Tune in now to hear why the most valuable medtech companies are built from the commercial endpoint backwards and what the strategics are actually looking for when they acquire.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠